Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder
Current and Emerging Drugs Will Not Surpass Vyvanse as the Clinical Gold Standard, According to a New Report From Decision Resources
WALTHAM, Mass., Jan. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issu...
Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
WASHINGTON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company,
presented today at a major scientific meeting findings from analyses of
pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound
is an investigational once-daily medic...
FDA Approves INTUNIV (guanfacine) for the Treatment of ADHD
...guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant
selective alpha-2A-receptor agonist, which has been studied in children and...o further strengthening our broad portfolio of ADHD medications by adding a nonstimulant
treatment option with a novel mechanism of action and demonstrated clinical...
Stimulant Medications More Effective In Treating ADHD Than Nonstimulants
...hen treated with stimulant medications rather than nonstimulant
medications or novel stimulants//. Researchers hav...re significantly more effective when compared with nonstimulant
medications such as modafinil.
This conclusio...s (E = 0.83 and E = 0.9 respectively), followed by nonstimulant
or modafinil based stimulants medications (E = 0.6...
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented
today at a major scientific meeting findings from analyses of pivotal trial
results of INTUNIV, a selective alpha-2A-agonist. This compound is an
Shire Announces Positive Results of Studies With Guanfacine
Extended Release, An Investigational Nonstimulant Medication Filed
for the Treatment of ADHD in Children and Adolescents
SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plc
announced today the positive results of studies of the
investigational medication guanfacine extended release (GXR,
previously referred to as SPD503), a selective
alpha-2A-adrenoceptor agonist. These data from two short-term phase